Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00767507 · ClinicalTrials.gov registry record · Phase 2
Maintenance of Platelet Inhibition With Cangrelor
A Phase 2 study of Acute Coronary Syndrome (ACS), sponsored by The Medicines Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 221
- Enrollment target
- 1
- Study location
NCT00767507: Completed Phase 2 study of Acute Coronary Syndrome (ACS), sponsored by The Medicines Company.
NCT00767507 is a Phase 2 study of Acute Coronary Syndrome (ACS) that has completed, run by The Medicines Company. The registered enrollment target is 221 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (66% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00767507, a Phase 2 study of Acute Coronary Syndrome (ACS), has completed, sponsored by The Medicines Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 221 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to demonstrate that patients receiving cangrelor infusion before coronary artery bypass grafting have an acceptable safety profile and can undergo surgery without excessive bleeding peri-operatively.
Primary Outcome
Endpoint was selected as an approximation of the antiplatelet effect expected to be maintained if oral P2Y12 inhibitors had not been discontinued (60% inhibition of platelets).
Conditions Studied
Interventions
- OTHER Placebo
- DRUG cangrelor
Study Locations (1)
California
- Scripps Clinic / Scripps Green Hospital - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 221 participants |
| Start Date | 2008-10 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
What the finished NCT00767507 record still lists
NCT00767507 is an interventional study that assigns participants to a tested intervention. The registered 221 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (66% higher).
The record links to 1 condition, with Acute Coronary Syndrome (ACS) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00767507 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00767507 about?
NCT00767507 is a clinical study titled "Maintenance of Platelet Inhibition With Cangrelor". The purpose of this study is to demonstrate that patients receiving cangrelor infusion before coronary artery bypass grafting have an acceptable safety profile and can undergo surgery without excessive bleeding peri-operatively.
What is the current status of trial NCT00767507?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 221 participants. The study started on 2008-10. Estimated completion is 2011-07.
What conditions does trial NCT00767507 study?
This clinical trial studies the following conditions: Acute Coronary Syndrome (ACS).
What interventions are being tested in trial NCT00767507?
The interventions under investigation include: Placebo (OTHER), cangrelor (DRUG).
Who is sponsoring clinical trial NCT00767507?
This trial is sponsored by The Medicines Company, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00767507 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Coronary Syndrome (ACS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00767507's enrollment target sits among peer trials
221 275th of 2000 higher than 1,726 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03170440 · 221 participants · NA
Non-invasive Nerve Stimulation for PTSD and Sleep
- NCT04939610 · 222 participants · Phase 1
A Study of 177Lu-FAP-2286 in Advanced Solid Tumors
- NCT05424783 · 222 participants
MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)
- NCT05568264 · 222 participants · NA
Effects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia